

SARS-CoV-2 infection in patients with chronic kidney disease on haemodialysis. Evolution of SARS-CoV-2 CRP[☆]

Infección por SARS-CoV-2 en pacientes con enfermedad renal crónica en hemodiálisis. Evolución de la PCR de SARS-CoV-2

Dear Editor,

We present a series of 21 patients with chronic kidney disease (CKD) on haemodialysis who were admitted due to SARS-CoV-2 infection, diagnosed by PCR of naso-oro-pharyngeal swab. The period of inclusion was from 11 March to 20 April 2020, monitoring the time to SARS-CoV-2 PCR negativisation. In the case of patients on a haemodialysis programme, it was necessary to monitor the SARS-CoV-2 PCR in order to decide on the period of isolation for these patients.

The median age was 75 years (between 50 and 89 years) with a higher prevalence of men (12 cases, 57%). Among the clinical history, all patients suffered from arterial hypertension (AHT), 15 (71%) from diabetes mellitus (DM), 9 (43%) from obesity, 10 (47%) from previous pulmonary disease, 6 (28%) from ischaemic heart disease, 6 (28%) from peripheral vascular disease, and 4 (19%) from cerebrovascular disease. Regarding antihypertensive treatment, 7 patients (33%) received calcium channel blockers, 4 (19%) ARBs, 4 (19%) ACE-1 inhibitors and 1 (4.7%) (Table 1).

All patients presented with some clinical manifestation, the most frequent was fever together with respiratory symptoms, and both were present in 87% of the cases, while 17 patients (80%) presented with pneumonia by Xray, which was bilateral in all of them. The laboratory variables on admission are shown in Table 2.

The treatment received was hydroxychloroquine in 17 patients (80.9%), azithromycin in 15 (71.4%), lopinavir/ritonavir in 5 (23.8%), ceftriaxone in 4 (19%), darunavir/cobicistat in 2 (9.5%), corticosteroids in one (4.7%) and tocilizumab in one (4.7%).

In the follow-up of the cases, one patient was admitted to the intensive care unit requiring invasive mechanical ventilation (without prone positioning) and the use of vasoactive drugs. Sixteen patients (76%) did not meet the criteria for admission to the ICU during the pandemic period. Six patients (28.5%) died. The presence of previous lung disease

was associated with mortality in 83.3% ($P = .038$). There were no statistically significant differences in relation to the laboratory variables or the treatment received.

Due to the need for isolation to perform the haemodialysis session in patients affected by SARS-CoV-2 infection, PCR was performed routinely every seven days approximately, and after the first negative result it was confirmed after 48 h according to protocol and then the isolation of the patient was discontinued. The mean time to negativisation was 22 days in the studied group. Two patients did not negativise the PCR during their hospitalisation.

The mortality of CKD patients on haemodialysis infected with SARS-CoV-2 was 28.5% and was associated with the presence of previous lung disease. Our results are in concordance with other previously published studies.¹⁻⁵

The high lethality of the infection in this population group is striking, and could be related to characteristics such as age, close contact with health personnel, in addition to the comorbidities present in this patient profile such as vasculopathy (in the form of ischaemic heart disease, cerebrovascular disease and peripheral arterial disease), as well as diabetes and lung diseases, already described in previous studies.⁶ In our cohort, it was associated with a history of lung disease.

The mean time to negativisation of the SARS-CoV-2 PCR of naso-oro-pharyngeal swab was 22 days and remained positive in two patients. Previous studies have shown that the persistence of positive PCR in respiratory samples was associated with greater severity, being 21 days in patients with severe symptoms and 14 days in cases of moderate disease.^{7,8}

It is interesting to mention that the correlation between positive SARS-CoV-2 PCR and infectivity is not clear after the remission of the symptoms; so cases where persistently positive by PCR and did not mean that persisted in an infective state.⁹ The same occurs in the cases of re-positivisation of SARS-CoV-2 PCR.¹⁰

We may conclude that SARS-CoV-2 infection in CKD patients on haemodialysis has an elevated mortality rate,

DOI of original article:

<https://doi.org/10.1016/j.nefro.2020.12.008>.

[☆] Please cite this article as: Zúñiga J, Toapanta N, Ramos N, Caparros S, León-Roman J, Azancot M, et al. Infección por SARS-CoV-2 en pacientes con enfermedad renal crónica en hemodiálisis. Evolución de la PCR de SARS-CoV-2. Nefrología. 2021.

<https://doi.org/10.1016/j.nefro.2020.12.008>

Table 1 – CKD patients on haemodialysis, admitted for SARS-CoV-2 infection.

| Characteristics | Total | Survivors | Deceased | P-value |
|------------------------------------|-----------|-----------|----------|-------------------|
| Female/male | 9/12 | 7/8 | 2/4 | .577 |
| Age | 75.6 | 74.4 | 78.6 | .659 |
| [0,1–5]Comorbidities | | | | |
| Arterial hypertension, n (%) | 21 (100) | 15 (100) | 6 (100) | 1 |
| Diabetes mellitus, n (%) | 15 (71.4) | 12 (80) | 3 (50) | .169 |
| Obesity, n (%) | 9 (42.8) | 6 (40) | 3 (50) | .676 |
| Lung disease, n (%) | 10 (47.6) | 5 (33.3) | 5 (83.3) | .038 ^a |
| Ischaemic heart disease, n (%) | 6 (28.5) | 3 (20) | 3 (50) | .169 |
| Stroke, n (%) | 4 (19) | 2 (13.3) | 2 (33.3) | .292 |
| Peripheral vascular disease, n (%) | 6 (28.5) | 5 (33.3) | 1 (16.6) | .445 |
| Active neoplasia, n (%) | 2 (9.5) | 1 (6.60) | 1 (16.6) | .747 |
| ACE inhibitor, n (%) | 1 (4.7) | 1 (6.6) | 0 | .517 |
| ARB, n (%) | 4 (19) | 4 (26.6) | 0 | .16 |
| Calcium channel blockers, n (%) | 7 (33.3) | 6 (40) | 1 (16.6) | .376 |

ARB: angiotensin II receptor blockers; CKD: chronic kidney disease; ACE inhibitor: angiotensin-converting enzyme inhibitor.

Table 2 – Laboratory variables at hospital admission.

| | Total (n: 21) | Survivors (n: 15) | Deaths (n: 6) |
|-------------------|--------------------|-------------------|---------------------|
| Creatinine, mg/dl | 5.69 (2.09–9.81) | 5.78 (2.09–9.81) | 5.46 (3.51–8.27) |
| Sodium, mmol/l | 135.86 (123–144) | 135.93 (123–144) | 135.7 (132.7–138.8) |
| Potassium, mmol/l | 4.33 (2.75–6.82) | 4.34 (2.75–6.82) | 4.33 (3.2–5.7) |
| Phosphate, mg/dl | 4.85 (2.1–9.9) | 5.06 (2.1–9.9) | 3.93 (3.1–4.8) |
| Calcium, mg/dl | 9.02 (7.8–10.5) | 8.91 (7.8–9.9) | 9.32 (8.2–10.5) |
| Ferritin, ng/ml | 1,506 (343–3361) | 1,525 (343–3361) | 1,358 (1179–1537) |
| IL-6, pg/dl | 288.7 (17.38–2016) | 317 (17.38–2016) | 154 (73.2–249.2) |
| D-dimer, ng/ml | 865.71 (172–3557) | 892.36 (172–3557) | 768 (377–1155) |
| LDH, IU/l | 468 (202–2475) | 491.75 (202–2475) | 373 (356–387) |

IL-6: interleukin-6; LDH: lactate dehydrogenase.

since one out of four hospitalised patients dies, although previous lung disease was associated with mortality. More studies are needed to define the appropriate timing to suspend isolation in patients with persistently positive PCR, which is of vital importance in the case of CKD patients receiving haemodialysis, since isolation requires a suitable centre, trained personnel, materials and transport arrangements, as well as concern for the family environment. The use of SARS-CoV-2 serologies offers a more clear picture of the temporality of the infection, as well as safety when ending the isolation of some patients.

Conflicts of interest

María José Soler declares that she has conducted scientific consulting work or given presentations for Mundipharma, Fresenius, Bayer, Novo Nordisk, Janssen, Boehringer, Eli Lilly, AstraZeneca and Esteve, not related to this study.

Clara García-Carro declares that she has conducted scientific consulting work, given scientific presentations and/or provided logistical support in organising scientific events for Astra Zeneca, Novo Nordisk, Boehringer Ingelheim, Astellas, Menarini, Novartis, Esteve and Sanofi, not related in any way to this study.

José Zúñiga, Néstor Toapanta, Natalia Ramos, Sonia Caparros, Juan León-Roman, María Azancot and Daniel Serón declare that they have no conflicts of interest.

REFERENCES

- Fontana F, Giaroni F, Frisina M, Alfano G, Mori G, Lucchi L, et al. SARS-CoV-2 infection in dialysis patients in northern Italy: a single-centre experience. *Clin Kidney J.* 2020;sfaa148, <http://dx.doi.org/10.1093/ckj/sfaa148>.
- Basile C, Combe C, Pizzarelli F, Covic A, Davenport A, Kanbay M, et al. Recommendations for the prevention, mitigation and containment of the emerging SARS-CoV-2 (COVID-19) pandemic in haemodialysis centres. *Nephrol Dial Transplant.* 2020;35:737–41, <http://dx.doi.org/10.1093/ndt/gfaa069>.
- Jager KJ, Kramer A, Chesnaye NC, Couchoud C, Sánchez-Álvarez JE, Garneata L, et al. Results from the ERA-EDTA Registry indicate a high mortality due to COVID-19 in dialysis patients and kidney transplant recipients across Europe. *Kidney Int.* 2020;98:1540–8, <http://dx.doi.org/10.1016/j.kint.2020.09.006>.
- Goicoechea M, Sánchez Cámara LA, Macías N, Macías N, Muñoz de Morales A, González Rojas A, et al. COVID-19: clinical course and outcomes of 36 hemodialysis patients in Spain. *Kidney Int.* 2020;98:27–34, <http://dx.doi.org/10.1016/j.kint.2020.04.031>.
- Valeri AM, Robbins-Juarez SY, Stevens JS, Ahn W, Rao MK, Radhakrishnan J, et al. Presentation and outcomes of patients with ESKD and COVID-19. *J Am Soc Nephrol.* 2020;31:1409–15, <http://dx.doi.org/10.1681/ASN.2020040470>.
- Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. *Int J Infect Dis.* 2020;94:91–5, <http://dx.doi.org/10.1016/j.ijid.2020.03.017>.

7. Liu Y, Yan LM, Wan L, Xiang TX, Le A, Liu JM, et al. Viral dynamics in mild and severe cases of COVID-19. *Lancet Infect Dis.* 2020;20:656–7, [http://dx.doi.org/10.1016/S1473-3099\(20\)30232-2](http://dx.doi.org/10.1016/S1473-3099(20)30232-2).
8. Xiao AT, Tong YX, Zhang S. Profile of RT-PCR for SARS-CoV-2: a preliminary study from 56 COVID-19 patients. *Clin Infect Dis.* 2020;71:2249–51, <http://dx.doi.org/10.1093/cid/ciaa460>.
9. Wölfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Müller MA, et al. Virological assessment of hospitalized patients with COVID-2019. *Nature.* 2020;581:465–9, <http://dx.doi.org/10.1038/s41586-020-2196-x>.
10. Roy S. COVID-19 reinfection: myth or truth? *SN Compr Clin Med.* 2020:1–4, <http://dx.doi.org/10.1007/s42399-020-00335-8>.

Servicio de Nefrología, Hospital Universitario Vall d'Hebron, Barcelona, Spain

* Corresponding author.

E-mail address: m.soler@vhebron.net

(M.J. Soler).

2013-2514/© 2021 Sociedad Española de Nefrología. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

<https://doi.org/10.1016/j.nefro.2020.12.006>

José Zúñiga, Néstor Toapanta, Natalia Ramos, Sonia Caparros, Juan León-Roman, María Azancot, Clara Garcia-Carro, Eugenia Espinel, Daniel Seron, María José Soler*

Severe COVID-19 in a patient with chronic kidney disease: Is there a positive effect of continuous venovenous hemodiafiltration?

COVID-19 grave en un paciente con enfermedad renal crónica: ¿hay un efecto positivo en la hemodiafiltración venosa continua?

Dear Editor,

Coronavirus disease 2019 (COVID-19) has been acknowledged pandemic by the World Health Organization. Critically ill cases of COVID-19 can develop severe complications (acute respiratory distress syndrome, multiple organ dysfunction, shock) or die.¹ COVID-19 has high morbidity and mortality in patients with chronic kidney disease (CKD).^{2,3} Here we report a severe case presentation in which a COVID-19 patient with CKD stage 4 had satisfactory outcome through timely continuous venovenous hemodiafiltration (CVVHDF).

On February 11, 2020, a 74-year-old woman was referred to our hospital for “fever for 14 days and dyspnea for 4 days”. Nine days before her admission, diagnosis of this patient was confirmed by a positive SARS-CoV-2 reverse transcriptase-polymerase chain reaction testing (RT-PCR) test and chest CT in clinic and the antiviral drug arbidol was taken orally. On admission, her oxygen saturation was maintained 95% on the use of bi-level positive airways pressure (BiPAP). Blood sample tests revealed lymphopenia, increased neutrophil ratio and inflammatory cytokines, such as IL-2, IL-2 receptor (IL-2R), IL-6 and tumor necrosis factor- α (TNF- α) (Table 1). She had chronic kidney disease for 5 years and serum creatinine was gener-

ally maintained at 200 μ mol/L for 2 years. However, her serum creatinine was 657 μ mol/L on admission which revealed acute kidney injury (AKI). CT scan on the day of admission showed ground-glass opacity in both lungs. We showed the most severe lesion in Fig. 1A. On the second day of admission, vascular access was obtained via a flexible double-lumen catheter placed in the femoral vein. The patient underwent CVVHDF for 5 consecutive days and each lasted about 10 h. Antivirus and antibiotics medications were also given. The patient released from the ventilator on the fifth day. Of note, plasma inflammatory cytokines concentrations and high-sensitivity C-reactive decreased after the CVVHDF (Table 1). Furthermore, serum creatinine decreased from 657 μ mol/l to 302 μ mol/l and remained stable within 7 days, and we removed the dialysis catheter. Chest CT showed remarkable absorption of lesions (Fig. 1B). From admission to discharge was totally 12 days.

The successful treatment of this patient arouses our thinking. Is there a positive effect of continuous venovenous hemodiafiltration? According to the literature, the positive role of continuous renal replacement therapy (CRRT) is still no consistent conclusion in critically ill patients.⁴ CRRT has been applied to critically ill patients, including patients with SARS-CoV, MERS-CoV and other viral infectious diseases such as Ebola virus disease due to its accurate volume control, steady acid-base and electrolyte correction, and achievement of hemodynamic stability.^{5,6} A meta-analysis revealed that the use of continuous venovenous hemofiltration (CVVH) in critically ill patients with sepsis or acute respiratory distress